科兴制药控股股东拟询价转让 近3月套现4.4亿A股募11亿

Core Viewpoint - The shareholder Shenzhen Koyi Pharmaceutical Holdings Co., Ltd. plans to transfer 10,062,800 shares of Sinovac Biotech, accounting for 5.00% of the company's total share capital, for its own operational development needs [1][2]. Group 1: Share Transfer Details - The transfer is a non-public transfer and will not be conducted through centralized bidding or block trading, meaning it is not a secondary market reduction [2][3]. - The transferee must be an institutional investor with appropriate pricing capability and risk tolerance [2]. - As of September 12, 2025, Koyi Pharmaceutical holds 119,751,430 shares, representing 59.50% of the company [2]. Group 2: Previous Share Transfers - On July 30, 2025, Koyi Pharmaceutical had previously planned to transfer 6,037,717 shares, which accounted for 3.00% of the total share capital, also for funding needs [3]. - The transfer price for the previous transaction was set at 36.70 CNY per share, totaling approximately 221.58 million CNY [3]. - Koyi Pharmaceutical had reduced its holdings by 5,989,200 shares between June 26 and July 9, 2025, at prices ranging from 32.84 to 48.37 CNY per share, amounting to a total of approximately 220.99 million CNY [3][4]. Group 3: Company Financials and Future Plans - Sinovac Biotech was listed on the Shanghai Stock Exchange on December 14, 2020, with an initial public offering (IPO) price of 22.33 CNY per share, raising a total of 1.11 billion CNY [4]. - The actual net fundraising was 995 million CNY, which was 710 million CNY less than the originally planned amount of 1.705 billion CNY [4]. - The company is currently planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries [5].